| Literature DB >> 29277970 |
Cédric Lemogne1,2,3, Monica Turinici2, Henri Panjo4, Charlotte Ngo1,5, Florence Canoui-Poitrine6,7, Jean-Christophe Chauvet-Gelinier8,9, Frédéric Limosin1,2,3, Silla M Consoli1,2, Marcel Goldberg10,11, Marie Zins10,11, Virginie Ringa4.
Abstract
The potential benefit of breast cancer screening is mitigated by the risk of false positives and overdiagnosis, thus advocating for a more personalized approach, based on the individual benefit-harm balance. Since personality might influence the women's appraisal of this balance, this prospective observational cohort study examined whether it could influence mammography use. A total of 2691 postmenopausal women of the GAZEL Cohort Study completed the Bortner Type A Rating Scale and the Buss and Durkee Hostility Inventory in 1993. Associations between personality scores and subsequent mammography use, self-reported through up to five triennial follow-up questionnaires, were estimated with Odds Ratio (OR) and 95% confidence interval (CI) with logistic mixed model regressions, adjusting for age, occupational grade, marital status, family history of breast cancer, age at menarche, age at first delivery, gynecological follow-up, hormone therapy use, and depressive symptoms. Individual propensity scores were used to weight the analyses to control for potential selection biases. More than 90% of the participants completed at least two follow-up questionnaires. Type A personality, but not hostility, was associated with mammography use in both univariate (crude OR [95% CI]: 1.62 [1.24-2.11], P < 0.001) and multivariate analyses (OR [95% CI]: 1.46 [1.13-1.90], P < 0.01). Type A personality traits (i.e., sense of time urgency, high job involvement, competitiveness) independently predicted mammography use among postmenopausal women. While paying more attention to the adherence of women with low levels of these traits, clinicians may help those with higher levels to better consider the risks of false positives and overdiagnosis.Entities:
Keywords: Breast neoplasms; cancer; cohort studies; early detection of cancer; mammography; oncology; personality
Mesh:
Year: 2017 PMID: 29277970 PMCID: PMC5806114 DOI: 10.1002/cam4.1268
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Characteristics of the participants at inclusion in this study (N = 2691) from the GAZEL cohort
| Continuous variables | Mean | SD |
|---|---|---|
| Age | 51.5 | 2.8 |
| Type A personality | 54.3 | 7.4 |
| Total hostility | 29.6 | 9.5 |
| Behavioral hostility | 6.8 | 3.4 |
| Cognitive hostility | 14.0 | 5.2 |
| Depressive symptoms | 16.4 | 10.5 |
Associations between mammography and each variable in this study (from the GAZEL cohort)
| Crude associations | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| Type A personality | 1.62*** | 1.24–2.11 | 1.70*** | 1.30–2.26 | 1.64*** | 1.23–2.20 | 1.44** | 1.10–1.90 | 1.67*** | 1.26–2.20 | 1.50** | 1.16–2.00 | 1.46** | 1.13–1.90 |
| Age | 1.90*** | 1.66–2.15 | 1.92*** | 1.70–2.20 | 1.90*** | 1.70–2.16 | 2.60*** | 2.21–3.00 | 1.91*** | 1.68–2.20 | 2.43*** | 2.09–2.82 | 2.64*** | 2.26–3.08 |
| Occupational grade | ||||||||||||||
| Blue‐collar workers, clerks | 0.65 | 0.40–1.04 | 0.70 | 0.41–1.10 | 0.62 | 0.40–1.02 | 0.80 | 0.50–1.24 | 0.66 | 0.40–1.08 | 0.86 | 0.55–1.36 | 0.74 | 0.47–1.17 |
| First‐line supervisors, sales representatives | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||
| Management | 0.67 | 0.34–1.35 | 0.61 | 0.30–1.30 | 0.55 | 0.30–1.15 | 0.60 | 0.30–1.17 | 0.61 | 0.30–1.24 | 0.60. | 0.30–1.20 | 0.60 | 0.30–1.16 |
| Marital status | ||||||||||||||
| Living as couple | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||||||
| Single, separated, divorced, widowed | 0.61* | 0.41–0.88 | 0.60** | 0.40–0.83 | 0.56** | 0.40–0.84 | 0.68 | 0.46–1.01 | 0.57** | 0.40–0.85 | 0.78** | 0.53–1.15 | 0.70 | 0.50–1.04 |
| Age at menarche | ||||||||||||||
| <11 years old | 1.13 | 0.38–3.31 | 0.86 | 0.30–2.65 | 0.83 | 0.30–2.22 | 0.88 | 0.32–2.43 | ||||||
| ≥11 years old | Ref. | Ref. | Ref. | Ref. | ||||||||||
| Age at first delivery | ||||||||||||||
| Nulliparous | 0.78 | 0.42–1.47 | 0.83 | 0.42–1.61 | 1.36 | 0.73–2.54 | 1.14 | 0.62–2.10 | ||||||
| <20 years old | 1.64 | 0.61–4.41 | 1.65 | 0.60–4.70 | 2.03 | 0.74–5.60 | 1.90 | 0.70–5.10 | ||||||
| 20–29 | Ref. | Ref. | Ref. | Ref. | ||||||||||
| ≥30 years old | 1.86 | 0.94–3.70 | 1.90 | 0.90–3.95 | 1.95 | 0.97–3.88 | 1.51 | 0.77–2.94 | ||||||
| Family history of breast cancer | ||||||||||||||
| Yes | 1.73 | 1.00–3.06 | 1.76 | 1.00–3.20 | 1.88* | 1.06–3.32 | 1.67 | 0.96–2.92 | ||||||
| No | Ref. | Ref. | Ref. | Ref. | ||||||||||
| Gynecological follow‐up | ||||||||||||||
| None | 0.03*** | 0.02–0.04 | 0.01*** | 0.01–0.02 | 0.02*** | 0.01–0.03 | 0.02*** | 0.01–0.03 | ||||||
| By a gynecologist | Ref. | Ref. | Ref. | Ref. | ||||||||||
| By a nongynecologist | 0.26*** | 0.17–0.40 | 0.20*** | 0.10–0.30 | 0.20*** | 0.11–0.30 | 0.20*** | 0.13–0.30 | ||||||
| Hormone therapy use | ||||||||||||||
| Yes | 3.25*** | 2.14–5.00 | 2.73*** | 1.76–4.24 | 2.00** | 1.30–2.90 | 1.90** | 1.30–2.83 | ||||||
| No | Ref. | Ref. | Ref. | Ref. | ||||||||||
| Depressive symptoms | 0.77* | 0.63–0.94 | 0.91 | 0.73–1.12 | ||||||||||
OR value are given normalized according to the interval between the 25th and the 75th percentile; *P < 0.05; **P < 0.01; ***P < 0.001.